InflaRx earnings beat by €0.11, revenue fell short of estimates
Investing.com - InflaRx (NASDAQ: IFRX) reported third quarter EPS of €-0.130, €0.11 better than the analyst estimate of €-0.238. Revenue for the quarter came in at €60.8K...
Neutral
or
InflaRx News & Analysis
-
-
InflaRx N.V. Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with INF904
InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today its topline results from the single ascending...
-
InflaRx's MAA for Vilobelimab Under Review by the EMA
InflaRx N.V. (Nasdaq: NASDAQ:IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the Company has submitted a...
-
InflaRx earnings beat by €0.17, revenue fell short of estimates
Investing.com - InflaRx (NASDAQ: IFRX) reported second quarter EPS of €-0.140, €0.17 better than the analyst estimate of €-0.313. Revenue for the quarter came in at €0.00...
-
InflaRx N.V. Appoints Camilla Chong as Chief Medical Officer
InflaRx N.V. (Nasdaq: NASDAQ:IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today...
-
InflaRx N.V. Announces US Commercial Launch of Gohibic
InflaRx N.V. (Nasdaq: NASDAQ:IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today the commercial launch of Gohibic...
-
InflaRx earnings beat by €0.02, revenue fell short of estimates
Investing.com - InflaRx (NASDAQ: IFRX) reported first quarter EPS of €-0.250, €0.02 better than the analyst estimate of €-0.265. Revenue for the quarter came in at €0.00...
-
H.C. Wainwright maintains InflaRx at Buy, PT $9.00
A H.C. Wainwright analyst maintained InflaRx (NASDAQ: IFRX) at Buy and a price target of $9.00 from a prior price target of %currency%%price%. Prior to this rating, InflaRx had 5 buy...
-
After-hours movers: PG&E falls on spot offering, Diamondback Energy gains potential asset sale
After-Hours Stock Movers: PG&E Corp. (NYSE:PCG) 2% LOWER; A 50 million share block of PG&E Corp. is said to be offered via Morgan Stanley at a price of $16.10-$16.40, according to...
-
InflaRx N.V. Announces Public Offering of Ordinary Shares
InflaRx N.V. (Nasdaq: NASDAQ:IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today...
-
H.C. Wainwright maintains InflaRx at Buy
A H.C. Wainwright analyst maintained InflaRx (NASDAQ: IFRX) at Buy and a price target of $10.00 from a prior price target of %currency%%price%. Prior to this rating, InflaRx had 5 buy...
-
InflaRx N.V. Halted Again on Volatility, Up 75%
InflaRx N.V. (IFRX) Halted Again on Volatility, Up 75%
-
LifeSci Capital upgrades InflaRx to Outperform
A LifeSci Capital analyst upgraded InflaRx (NASDAQ: IFRX) from Market Perform to Outperform with a price target of $No data. Prior to this rating, InflaRx had 4 buy ratings, 1 hold ratings,...
-
After-hours movers: J&J gains on another talc settlement, InflaRx adds on FDA EUA
After-Hours Stock Movers: InflaRx N.V. (NASDAQ:IFRX) 26% HIGHER; adds to gains of 84% intra-day on an FDA EUA approval for its COVID-19 treatment for critically ill patients. SMART Global...
-
InflaRx N.V. Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that Gohibic...
-
InflaRx N.V. Halted on Volatility
InflaRx N.V. (IFRX) Halted on Volatility
-
InflaRx earnings beat by €0.07, revenue topped estimates
Investing.com - InflaRx (NASDAQ: IFRX) reported first quarter EPS of €-0.180, €0.07 better than the analyst estimate of €-0.246. Revenue for the quarter came in at €1.84M...
-
InflaRx earnings beat, Revenue Inline in Q3
Investing.com - InflaRx reported on Wednesday third quarter {{erl-1054800||earnings that beat analysts' forecasts and revenue that was inline with expectations. InflaRx announced earnings...
-
InflaRx Stock Upgraded after Positive Data from Phase 2 Study
By Sam Boughedda Investing.com — InflaRx N.V. (NASDAQ:IFRX) stock surged Thursday on heavy volume after it reported positive data from the third cohort of patients in the Phase 2a study for...
-
U.S. shares lower at close of trade; Dow Jones Industrial Average down 4.44%
Investing.com – U.S. equities were lower at the close on Wednesday, as losses in the Utilities, Financials and Industrials sectors propelled shares lower. At the close in NYSE, the Dow...
-
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.82%
Investing.com – U.S. equities were higher at the close on Wednesday, as gains in the Utilities, Consumer Goods and Financials sectors propelled shares higher. At the close in NYSE, the Dow...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
